SPACEYour Medical Portal

We’re for the safety-conscious

Safety

EYLEA 8mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular 
oedema (DME).

The reassurance of treating your patients with the tried-and-trusted aflibercept molecule

EYLEA 8mg had a safety profile consistent with EYLEA 2mg through Week 96:

No new or unexpected adverse events

AEs in patients receiving EYLEA 8mg were consistent with EYLEA 2mg

No new or unexpected adverse events

Adapted from Sivaprasad S, et al. 2024.

 

Comparable IOP rates

IOP values were similar to EYLEA 2mg through Week 96

Comparable IOP rates

Adapted from Sivaprasad S, et al. 2024.

 

Comparable IOI rates

IOI values were similar to EYLEA 2mg through Week 96

Comparable IOI rates

Adapted from Sivaprasad S, et al. 2024.

 

All IOI cases were mild or moderate in severity, except for one case
of severe endophthalmitis.

Explore
Why a higher dose of EYLEA?
Learn more about the EYLEA Mode of Action
Dosing
Discover the posology of EYLEA 8mg
How to inject EYLEA 8mg
Learn the key steps in injecting EYLEA 8mg

  • 2q8: 2mg every 8 weeks

    8q12: 8mg every 12 weeks.

    8q16: 8mg every 16 weeks.

    AE: adverse events.

    APTC: antiplatelet trialists' collaboration.

    DME: diabetic macular oedema.

    IOI: intraocular inflammation.

    IOP: intraocular pressure.

    q8: every 8 weeks.

    SAE: serious adverse event.

    SAF: safety analysis set.
     

Next Page
Dosing
    • 1
      EYLEA® 8mg (aflibercept 114.3 mg/mL, solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
    • 2
      Sivaprasad S, et al. BCVA gains with aflibercept 8 mg maintained through Week 96 in PULSAR with extended treatment intervals in patients with nAMD. ARVO. 5–9 November 2024. Seattle, USA. Oral presentation.
    • 3
      Do D. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. Angiogenesis, Exudation and Degeneration. 3 February 2024. Palo Alto, USA. Oral presentation.
    • a
       EYLEA 2mg was dosed at fixed q8 intervals after 3 (nAMD) or 5 (DME) initial monthly injections.³٬⁵
    • b
      Any ocular treatment-emergent AE in the study eye.²-⁴
    • c
      Ocular TEAEs occurring in ≥5% of patients in any treatment group were cataract, retinal haemorrhage, visual acuity reduced and vitreous floaters.²
    • d
      Treatment-emergent events.²-⁵
    • e
      All events.²-⁵
    • f
      Ocular AEs occurring in ≥5% of patients in any treatment group were cataract, vitreous floaters and conjunctival haemorrhage.³